USC team reveals structure of APOBEC family protein

December 24, 2006

Researchers at the University of Southern California have provided the first 3-D view of a protein from an enzyme family that, through its ability to mutate genes, can both help and hinder human health.

Reporting in the Dec. 24 online edition of Nature, a USC team led by Xiaojiang Chen revealed the "unusual" crystal structure of the Apo2 enzyme.

"This three-dimensional structure offers the first mechanistic analysis of any of the APOBEC enzymes at the molecular level. These proteins are important for understanding a number of critical biological processes, such as the generation of high-affinity antibodies in response to a virus or other infection," said Chen, the study's senior author and a professor of biological sciences and chemistry in USC College.

A structural biologist, Chen has produced the first x-ray crystal structures of a number of proteins important in viruses, cancer and immunity.

In one sense, the APOBEC proteins are classic saboteurs -- they all can introduce mutations into strands of DNA or RNA. Known as deaminases, APOBEC proteins catalyze a chemical reaction that changes the "C" (cytidine) of the genetic code into a "U" or (uracil). Even a one-letter change in the code can lead to a change or loss of function in an encoded protein.

Looked at from a different perspective, however, the enzyme family plays a decidedly protective role in the cell. One notable family member, the AID protein, generates the genetic diversity required for the body to produce hundreds of billions of different antibodies, each capable of targeting a specific disease-causing agent. Others have been shown to disarm viruses like HIV and hepatitis B.

Uncontrolled, of course, the APOBEC proteins could create havoc in a cell. But normally, under the cell's tight regulation, "these are the good guys," Chen said.

When Courtney Prochnow, a graduate student in Chen's lab, first revealed the atomic structure of the enzyme, the research team was surprised by the molecule's shape.

"Based on what is known about proteins that catalyze a similar chemical reaction, we expected it to look more like a square. But instead, it resembles a butterfly," Chen said. "It's significant because this non-canonical, butterfly shape provides new, plausible explanations of an immune deficiency disease at the molecular level."

With the Apo2 structure in hand, the team was able to deduce what likely goes wrong in patients with the rare, serious immune disorder hyper-IgM immunodeficiency syndrome type 2, or HIGM-2. The syndrome is characterized by mutations in the gene encoding AID, the activation-induced cytidine deaminase protein, and a weakened immune system.

USC biochemist Myron Goodman and his former graduate student Ronda Bransteitter collaborated with Chen's group to examine how the genetic mutations common in HIGM-2 patients might affect the structure, and therefore the function, of the AID enzyme. A professor of biological sciences and chemistry at USC College, Goodman has previously done groundbreaking work on AID and the related Apo3 APOBEC enzymes.

Using the Apo2 results as a guide, the team revealed new details about how these mutations translate into a loss of AID activity. They showed that some mutations stop AID from folding and therefore working properly, while others block its ability to interact with DNA and RNA molecules.

"The x-ray structure of Apo2 provides a clear direction for research on therapeutic strategies to deal with problems arising from either the failure of one of the APOBEC enzymes to function properly, as in HIGM-2, or from the potentially more serious problem of an enzyme working at inappropriate times and places, leading to genetic mutations that may cause cancer and other diseases," Chen said.
-end-


University of Southern California

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.